Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.

[1]  R. Bouabdallah,et al.  PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study , 2020 .

[2]  J. Connors,et al.  Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy , 2020, Leukemia & lymphoma.

[3]  O. Casasnovas,et al.  Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials , 2020, Cancer medicine.

[4]  R. Advani,et al.  Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  I. Flinn,et al.  Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress). , 2020 .

[6]  J. Friedberg,et al.  An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. , 2020 .

[7]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. , 2019, Blood.

[8]  Sonali M. Smith,et al.  Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. , 2019, Blood.

[9]  R. Bouabdallah,et al.  PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. , 2019, The Lancet. Oncology.

[10]  N. Kalakonda,et al.  Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial , 2018, The Lancet. Oncology.

[11]  A. Shimoni,et al.  Second Malignancies after Hematopoietic Stem Cell Transplantation , 2018, Current Treatment Options in Oncology.

[12]  A. Rossi,et al.  Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[14]  J. Connors,et al.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma , 2017, The New England journal of medicine.

[15]  M. Sydes,et al.  Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials , 2017, Haematologica.

[16]  J. Radford,et al.  RESPONSE‐ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE‐ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). , 2017 .

[17]  R. Gascoyne,et al.  Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. d'Amore,et al.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.

[19]  J. Auger,et al.  Impact of lymphoma treatments on spermatogenesis and sperm deoxyribonucleic acid: a multicenter prospective study from the CECOS network. , 2014, Fertility and sterility.

[20]  V. Diehl,et al.  Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. , 2013, Journal of Clinical Oncology.

[21]  J. Armitage,et al.  Positron emission tomographic scans in lymphoma: convention and controversy. , 2012, Mayo Clinic proceedings.

[22]  Scott E. Smith,et al.  A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. , 2012, Blood.

[23]  V. Diehl,et al.  Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). , 2008, Blood.

[24]  P. Hall,et al.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  V. Diehl,et al.  Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Radford,et al.  Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records , 1997, BMJ.

[27]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.